文献速递艾滋病与性传播感染

每日一次依曲韦林/拉替拉韦(400/800 mg q24h)双药方案在HIV感染者中维持48周病毒抑制

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

这项前瞻性、多中心、开放标签、单臂研究纳入111例已接受依曲韦林/拉替拉韦每日两次(q12h)方案且病毒抑制至少96周的HIV感染者,换用每日一次(q24h)400/800 mg方案。48周病毒学失败率为2.0%(95% CI 0.5-7.8),治疗策略成功率为89%(95% CI 81.5-93.6),表明每日一次双药方案可有效维持病毒抑制。

要点

  • 每日一次依曲韦林/拉替拉韦(400/800 mg q24h)在已抑制患者中48周病毒学失败率仅2.0%。
  • 治疗策略成功率(无病毒学失败且无治疗中断)为89%。
  • 2例病毒学失败者均有既往NNRTI突变,其中1例出现INSTI耐药。

核心结论

  • 将已接受依曲韦林/拉替拉韦q12h且病毒抑制的患者换用相同药物q24h方案,可高效维持病毒学抑制。

研究设计与样本

  • 前瞻性、多中心、开放标签、单臂研究,纳入111例已接受依曲韦林/拉替拉韦q12h至少96周且病毒抑制的HIV感染者。
  • 患者换用依曲韦林/拉替拉韦400/800 mg q24h,主要终点为48周病毒学失败率。

主要发现

  • 48周病毒学失败率为2.0%(95% CI 0.5-7.8),2例病毒反弹分别发生在第24周和第48周。
  • 48周治疗策略成功率为89%(95% CI 81.5-93.6)。
  • 10例患者中断治疗,原因包括不良事件(n=2)、研究者或患者决定(n=3)、失访(n=3)、死亡(n=1)和妊娠(n=1)。
  • 64例亚组中,依曲韦林和拉替拉韦的中位(IQR)血浆C24h浓度分别为401 ng/mL(280-603)和62 ng/mL(31-140)。

关键数值与推荐

  • 病毒学失败定义:确认pVL >50 copies/mL,或单次pVL >400 copies/mL,或单次pVL >50 copies/mL且伴随抗逆转录病毒治疗更改。
  • 入组患者中位(IQR)年龄57岁(52-62),CD4计数710 cells/mm3(501-919),病毒抑制持续时间7.9年(5.9-10.7)。

临床怎么用

  • 对于已接受依曲韦林/拉替拉韦q12h且病毒抑制至少96周的HIV感染者,可考虑换用q24h方案以简化治疗。
  • 换用前应评估既往NNRTI突变史,因病毒学失败者均有既往NNRTI突变。

局限性

  • 单臂、开放标签设计,无对照组。
  • 样本量较小(111例),病毒学失败事件数少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study. OBJECTIVES: As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h. METHODS: Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF. RESULTS: A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52-62), CD4 count of 710 cells/mm3 (501-919) and viral suppression for 7.9 years (5.9-10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5-7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5-93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280-603) for etravirine and 62 ng/mL (31-140) for raltegravir. CONCLUSIONS: Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Palich R, Allavena C, Peytavin G, et al. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. J Antimicrob Chemother. 2021. PMID: 33099638. doi:10.1093/jac/dkaa423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。